Author Index Volume 27 (2015)
The issue number is given in front of the page numbers
Acheampong, F., E. Bruce and B.P. Anto, Medication safety activities of hospital pharmacists in Ghana; challenges and perceived impact on patient care (1) 1–10
Adeoti, A.O., see Fadare, J.O. (4) 177–189
Agboola, S.M., see Fadare, J.O. (4) 177–189
Aina, F.O., see Fadare, J.O. (4) 177–189
Anantachoti, P., see Kaewpanukrungsi, W. (4) 225–237
Anto, B.P., see Acheampong, F. (1) 1–10
Antonuccio, D.O., see Högberg, G. (2) 85–91
Attard-Montalto, S., see Ellul, I.C. (3) 123–134
Bahl, A., see Kannan, S. (4) 219–223
Banerjee, M., see Bhowmick, S. (2) 101–102
Barati, O., see Khammarni, M. (4) 169–175
Barrett, C., see Darbyshire, D. (1) 23–33
Bavdekar, S.B., see Jobanputra, N. (3) 113–121
Bhardwaj, A., see Kannan, S. (2) 77–83
Bhowmick, S., P. Pal, B. Chakraborty, S. Sikdar, S. Chakraborty, M. Banerjee and A. Kundu, Letter to the Editor (2) 101–102
Boleat, E., see Griffiths, S.E. (4) 201–207
Bruce, E., see Acheampong, F. (1) 1–10
Bugden, S., see Hamilton, K. (4) 191–199
Card, A.J., see Simsekler, M.C.E. (2) 67–76
Chakraborty, B., see Bhowmick, S. (2) 101–102
Chakraborty, S., see Bhowmick, S. (2) 101–102
Clarkson, P.J., see Simsekler, M.C.E. (2) 67–76
D’Cruz, S., see Kashyap, M. (4) 209–217
Darbyshire, D., C. Barrett, D. Ross and D. Shackley, Measuring ward round quality in urology (1) 23–33
Davis, C., see Hamilton, K. (4) 191–199
Desalu, O.O., see Fadare, J.O. (4) 177–189
Drumond, N., see Gromek, K. (2) 55–65
Ellul, I.C., V. Grech and S. Attard-Montalto, Paediatric off-label and unlicensed prescribing in primary care in Malta: Prospective observational drug utilisation study (3) 123–134
Fadare, J.O., O.O. Desalu, A.M. Obimakinde, A.O. Adeoti, S.M. Agboola and F.O. Aina, Prevalence of inappropriate medication prescription in the elderly in Nigeria: A comparison of Beers and STOPP criteria (4) 177–189
Falk, J., see Hamilton, K. (4) 191–199
Gangadhar, B.N., see Rao, M.G. (3) 153–157
Goodwin, A., see Griffiths, S.E. (4) 201–207
Goonasekera, C., see Griffiths, S.E. (4) 201–207
Gowri, S., see Kannan, S. (2) 77–83
Grech, V., Atomic bomb testing and its effects on global male to female ratios at birth (1) 35–44
Grech, V., Response to a Letter to the Editor (2) 111–112
Grech, V., see Ellul, I.C. (3) 123–134
Griffiths, S.E., E. Boleat, A. Goodwin, A. Sheikh and C. Goonasekera, Efficacy of paediatric anaesthetic trolleys: A call for a basic standard and layout (4) 201–207
Gromek, K., N. Drumond and P. Simas, Pharmacovigilance of herbal medicines (2) 55–65
Hamilton, K., C. Davis, J. Falk, A. Singer and S. Bugden, High risk use of OTC NSAIDs and ASA in family medicine: A retrospective chart review (4) 191–199
Healy, D., see Högberg, G. (2) 85–91
Högberg, G., D.O. Antonuccio and D. Healy, Suicidal risk from TADS study was higher than it first appeared (2) 85–91
Jain, R., see Kannan, S. (2) 77–83
Jobanputra, N., S.U. Save and S.B. Bavdekar, Off-label and unlicensed drug use in children admitted to Pediatric Intensive Care Units (PICU) (3) 113–121
Kaewpanukrungsi, W. and P. Anantachoti, Performance assessment of the Thai National Center for Pharmacovigilance (4) 225–237
Kannan, S., A. Bahl and P.P. Khosla, Knowledge and perception of off-label drug use amongst prescribing physicians in a tertiary care hospital (4) 219–223
Kannan, S., S. Gowri, V. Tyagi, S. Kohli, R. Jain, P. Kapil and A. Bhardwaj, Direct-to-physician and direct-to-consumer advertising: Time to have stringent regulations (2) 77–83
Kapil, P., see Kannan, S. (2) 77–83
Kashyap, M., S. D’Cruz, A. Sachdev and P. Tiwari, Evidence-based information leads to reduction in inappropriate drug prescribing: Results from Indian older inpatients (4) 209–217
Keshtkaran, A., see Khammarni, M. (4) 169–175
Khammarni, M., R. Sharifian, A. Keshtkaran, F. Zand, O. Barati, E. Khonia and F. Setoodehzadeh, Prescribing errors in two ICU wards in a large teaching hospital in Iran (4) 169–175
Khonia, E., see Khammarni, M. (4) 169–175
Khosla, P.P., see Kannan, S. (4) 219–223
Kohli, S., see Kannan, S. (2) 77–83
Körblein, A., Concerning a Letter to the Editor (2) 103–105
Kundu, A., see Bhowmick, S. (2) 101–102
Kurutkan, M.N., E. Usta, F. Orhan and M.C.E. Simsekler, Application of the IHI Global Trigger Tool in measuring the adverse event rate in a Turkish healthcare setting (1) 11–21
Lalwani, T., see Saiyed, M.M. (1) 45–53
Lexchin, J., Formulary status of drugs in Ontario after Health Canada has issued a serious safety warning: A cohort study (3) 135–142
Obimakinde, A.M., see Fadare, J.O. (4) 177–189
Orhan, F., see Kurutkan, M.N. (1) 11–21
Pal, P., see Bhowmick, S. (2) 101–102
Rana, D., see Saiyed, M.M. (1) 45–53
Rao, M.G., S. Varambally, G. Venkatasubramanian and B.N. Gangadhar, Hazards of antihistamine dependence in psychiatric patients: A case report (3) 153–157
Ross, D., see Darbyshire, D. (1) 23–33
Sachdev, A., see Kashyap, M. (4) 209–217
Saiyed, M.M., T. Lalwani and D. Rana, Is off-label use a risk factor for adverse drug reactions in pediatric patients? A prospective study in an Indian tertiary care hospital (1) 45–53
Save, S.U., see Jobanputra, N. (3) 113–121
Scherb, H., Comment on a Letter to the Editor (2) 107–110
Setoodehzadeh, F., see Khammarni, M. (4) 169–175
Shackley, D., see Darbyshire, D. (1) 23–33
Sharifian, R., see Khammarni, M. (4) 169–175
Sheikh, A., see Griffiths, S.E. (4) 201–207
Sikdar, S., see Bhowmick, S. (2) 101–102
Simas, P., see Gromek, K. (2) 55–65
Simsekler, M.C.E., A.J. Card, J.R. Ward and P.J. Clarkson, Trust-level risk identification
guidance in the NHS East of England (2) 67–76
Simsekler, M.C.E., see Kurutkan, M.N. (1) 11–21
Singer, A., see Hamilton, K. (4) 191–199
Tiwari, P., see Kashyap, M. (4) 209–217
Tyagi, V., see Kannan, S. (2) 77–83
Urato, A.C., Are the SSRI antidepressants safe in pregnancy? Understanding the debate (2) 93–99
Usta, E., see Kurutkan, M.N. (1) 11–21
Varambally, S., see Rao, M.G. (3) 153–157
Venkatasubramanian, G., see Rao, M.G. (3) 153–157
Ward, J.R., see Simsekler, M.C.E. (2) 67–76
Zand, F., see Khammarni, M. (4) 169–175
